trametinib Jun 23, 2022 Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Apr 26, 2022 Novartis Q1 Revenues Grow 1 Percent Amid Organizational Restructuring, Shifting Growth Drivers Mar 17, 2022 NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers Feb 3, 2022 Novartis Anticipating Radioligands, New Precision Therapies to Continue Oncology Segment Growth Premium Feb 2, 2022 Novartis Q4 Revenues Increase 4 Percent Bolstered by Oncology Drug Sales Dec 9, 2021 SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance Dec 8, 2021 Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma Nov 24, 2021 Opdivo-Yervoy Before Tafinlar-Mekinist Provides Optimal Benefit to BRAF-Mutant Melanoma Patients Premium Aug 17, 2021 Turning Point Therapeutics Begins Study of Repotrectinib, Mekinist in KRAS G12D-Mutated Cancers Jul 21, 2021 Novartis Q2 Revenues Grow 14 Percent Jul 1, 2021 Deciphera Pharmaceuticals Begins ULK Kinase Inhibitor Study in RAS-, RAF-Mutated Cancers Apr 29, 2021 High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds Premium Feb 16, 2021 Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Sep 25, 2020 Novartis Melanoma Triplet Therapy Failure Raises Questions for Other Combos; Subgroups May Benefit Premium Aug 18, 2020 Patients With BRAF-Mutated Bile Duct Cancer See Benefit from Targeted Treatment Combination Premium Apr 28, 2020 AACR Studies in BRAF-Mutated Melanoma Show Benefit of Combo Treatment, Continuous Dosing Strategies Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
